Anti-Human IL-6 (Serum), polyclonal antibody
- Known as:
- Antibody toHuman Interleukin-6 (Serum), pab (anti-)
- Catalog number:
- RF0044
- Product Quantity:
- 100 μl lyophilized
- Category:
- -
- Supplier:
- Agren
- Gene target:
- Anti-Human IL-6 (Serum) polyclonal antibody
Related genes to: Anti-Human IL-6 (Serum), polyclonal antibody
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Anti-Human IL-6 (Serum), polyclonal antibody
Related articles to: Anti-Human IL-6 (Serum), polyclonal antibody
- Hermansky-Pudlak Syndrome (HPS) type 1 (HPS-1) is an autosomal recessive disorder characterized by oculocutaneous albinism, platelet dysfunction, and pulmonary fibrosis (HPS-PF), the leading cause of mortality in these patients. HPS-PF manifests earlier than idiopathic pulmonary fibrosis, typically between 30 and 40 years of age. The etiology and drivers of HPS-PF progression remain poorly understood, and no FDA-approved therapies exist. Neutrophil extracellular traps (NETs) and neutrophil-derived mediators have emerged as key players in fibrosis, promoting lung injury, inflammation, and fibroblast activation. This study evaluates the role of neutrophil activation in age-related changes in patients with HPS-1, focusing on differences in inflammatory markers, neutrophil granules, and NETosis capacity. We observed significantly elevated levels of NETs, neutrophil granule proteins (NE, NGAL, LF), and inflammatory cytokines (IL-8, IL-6) in patients with HPS-1 older than 40 years compared to younger patients and healthy controls. Additionally, fibrosis-related markers (MMP-7 and MMP-8) were significantly higher in older patients. Elevated levels of anandamide (AEA), a circulating marker of HPS-PF, were positively associated with neutrophil granule markers in older patients, suggesting its association with fibrosis. Neutrophils from older patients also demonstrated increased NETosis capacity. These findings suggest that age-related neutrophil activation may contribute to an inflammatory environment that promotes fibrosis progression in HPS-1. - Source: PubMed
Publication date: 2025/05/12
Caro-Rivera Lourdes MarinnaMalavez-Cajigas SonyaLacourt-Ventura MercedesRivera-Torres Andrea PMarcano-Jiménez Dorca ELópez-Colon PabloMuñiz-Hernández JoséRivera-Jiménez EnidEgozcue-Dionisi MónicaRomán-Carlo RosaDe Jesús-Rojas WilfredoRamos-Benítez Marcos J - Ischemic stroke is a leading cause of mortality and disability worldwide, yet effective therapeutic options remain limited. In this study, bioinformatics analyses were used to identify potential therapeutic targets and small-molecule compounds for ischemic stroke. A mouse model of cerebral ischemia was subsequently used to validate their neuroprotective efficacy. - Source: PubMed
Publication date: 2025/05/12
Zhao ShiyanLu JunZhao YanyanQi ChangHan Chunrong - This study aims to evaluate the anticancer properties of chamomile nano-emulsion (Cha-NE) and α-lactalbumin (α-LA) coated Cha-NE (LA-Cha-NE) against breast tumor through both in vitro and in vivo investigations. Both Cha-NE and LA-Cha-NE exhibited typical semi-spherical forms under Transmission electron microscope (TEM), and displayed surface charges of 46.75 and 28.45 mV with average sizes of 87.46 and 112.75 nm, respectively. In a safe manner, Cha-NE and LA-Cha-NE showed higher selectivity against breast cancer (MDA-MB-231 and MCF7) cells than normal (HSF) cells. Reductions in serum contents of IL1β, TNF-α, IL-4, IL-6, IL-10, ASAT, ALAT, creatinine, urea, triglycerides, and cholesterol, as well as an the administration of LA-Cha-NE, breast tumor incidence dramatically reduced. Thus, improvement in survival rates leads to successful prevention of mammary tumorigenesis as proved by the histopathological and immunohistochemistry findings. However, there was an increase in mammary GSH, GPx, CAT, and SOD activity. Both in vitro and in vivo investigations showed that LA-Cha-NE had a beneficial therapeutic effect, exhibiting more significantly regulated apoptosis and elevated expression of genes that regulate the cell cycle. Thus, this study demonstrated that the chemo-preventive property of LA-Cha-NE may offer a brand-new alternative therapy to cure breast cancer by re-establishing the compromised oxidative stress response, enhancing the immune response, reducing inflammation process, and fortifying the apoptosis pathway. - Source: PubMed
Publication date: 2025/05/13
Alkhathami Ali GAshry MahmoudAl Kamaly OmkulthomEl-Sayed Mohamed HAtwa AhmedEl-Fakharany Esmail M - Colitis is a multifactorial inflammatory bowel disease (IBD) involving intestinal barrier dysfunction, immune dysregulation, oxidative stress, and microbiota imbalance. Lactobacillus salivarius (L. salivarius), a probiotic with antioxidative and anti-inflammatory properties, was evaluated in a mouse model of DSS-induced colitis. Treatment with L. salivarius significantly reduced weight loss, colon shortening, and disease activity index, while improving histopathological damage. DSS-induced colitis exhibited significant oxidative stress, evidenced by decreased total antioxidant capacity, increased malondialdehyde (MDA), and reduced activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). After the intervention of L. salivarius, MDA levels in colon tissues decreased significantly, while SOD and GSH-Px activities increased significantly. In DSS-induced colitis models, the expression of pro-inflammatory cytokines (such as TNF-α, IL-6, IL-1β) was significantly increased, while the expression of anti-inflammatory cytokine IL-10 was decreased. After the intervention of L. salivarius, the level of proinflammatory factors was significantly down-regulated, while the level of IL-10 was up-regulated. DSS treatment leads to a significant imbalance in the intestinal microbiota, characterized by an increase in the ratio of Firmicutes to Bacteroidetes (F/B ratio). The abundance of pathogenic bacteria (Alistipes, Candidatus_Soleaferrea, Frisingicoccus, Romboutsia, Streptococcus) increased, while beneficial bacteria (Anaerotruncus, Rikenella) decreased. After probiotic administration, the F/B ratio was restored significantly, and the abundance of important beneficial bacteria increased while the abundance of pathogenic bacteria decreased. These results suggest that L. salivarius alleviates DSS-induced colitis by enhancing antioxidant defense, regulating inflammatory responses, and restoring gut microbiota balance. This probiotic may offer a promising therapeutic strategy for managing ulcerative colitis (UC). - Source: PubMed
Publication date: 2025/05/10
Ma JinpingWu DaoyiXu ChangHe QingWang MingjinImran MuhammadNazar MudassarLi Kun - Six novel chalcones were synthesized, and their structures were confirmed using various spectral tools. All the prepared compounds were subjected to SRB cytotoxic screening against nine cancer and two normal cell lines. Compound 7a showed the highest impact against colorectal carcinoma (HCT116) and cervical cancer (Hela) with IC values of 4.6±0.03 and 5.5±0.1 μg/mL, respectively, compared to doxorubicin (4.8±0.4 and 5.7±0.4 μg/mL, respectively). ELISA assay revealed that the apoptotic proteins (P53, Bax, caspases-3, -8, and -9) and the oxidative marker (Malondialdehyde (MDA)) were significantly activated in 7a treated HCT116 and Hela cells. However, the anti-metastatic markers (Matrix metalloproteinase 2 (MMP2) and Matrix metalloproteinase-9 (MMP9)), anti-apoptotic Bcl2, antioxidant Glutathione (GSH), and anti-inflammatory (interleukin (IL)-6, and IL-1β) were inhibited in HCT116 and Hela cells treated with 7a. Flow-cytometric analysis of the cell cycle revealed that the percentage of cells in S and G2/M phases in 7a treated HCT116 cells was increased. After 24 hours of treatment, Hela-treated cells had a slightly higher proportion of G0/G1 cells. Comet assay demonstrated that compound 7a caused DNA damage with a percentage of 26.22±1.1% in HCT116 compared to the untreated cells (6.18±0.88%). Theoretical molecular modeling against P53 cancer mutant Y220C and Bcl2 showed binding energies of -22.7 and -23.3 Kcal/mol, respectively, which confirmed our ELISA results. - Source: PubMed
Publication date: 2025/05/10
Ibrahim Nada SShoukry Eman HatemSharaky MarwaDiab Hadeer MElwahy Ahmed H MAbdelhamid Ismail A